"Revlimid Litigation is delayed and the trial is now expected to begin in Q2FY21. Revlimid is a large opportunity as it could add more than $500 million net present value even in the worst case," said Credit Suisse.
Wednesday, 18 December 2019
Shares Of Dr Reddy’s Laboratories Climbed By Over A Percent In Morning Trade
"Revlimid Litigation is delayed and the trial is now expected to begin in Q2FY21. Revlimid is a large opportunity as it could add more than $500 million net present value even in the worst case," said Credit Suisse.
Subscribe to:
Post Comments (Atom)
Trends On SGX Nifty Indicate A Positive Opening For The Broader Index In India
Trends on SGX Nifty indicate a positive opening for the broader index in India, with a 31.5 points gain or 0.25 percent. The Nifty future...
-
Prime Minister Narendra Modi-led National Democratic Alliance government's sixth and final budget before the polls due in April-May i... -
Maruti Suzuki India share price added 1.5 percent in the early trade on December 17 after foreign research house Bank of America Merrill ... -
Shares of Bandhan Bank rallied nearly 9 percent intraday on October 15 ahead of addition in the MSCI index tomorrow. Gruh Finance also g...
No comments:
Post a Comment